0001140361-24-017682.txt : 20240403 0001140361-24-017682.hdr.sgml : 20240403 20240403180043 ACCESSION NUMBER: 0001140361-24-017682 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230728 FILED AS OF DATE: 20240403 DATE AS OF CHANGE: 20240403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KNIGHT THERAPEUTICS INTERNATIONAL SA CENTRAL INDEX KEY: 0001632373 ORGANIZATION NAME: STATE OF INCORPORATION: X3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41719 FILM NUMBER: 24820539 BUSINESS ADDRESS: STREET 1: DR LUIS BONAVITA 1294 STREET 2: OFFICE 2004 CITY: MONTEVIDEO STATE: X3 ZIP: 11300 BUSINESS PHONE: 982-626-2344 MAIL ADDRESS: STREET 1: DR LUIS BONAVITA 1294 STREET 2: OFFICE 2004 CITY: MONTEVIDEO STATE: X3 ZIP: 11300 FORMER NAME: FORMER CONFORMED NAME: Knight Therapeutics (Barbados) Inc. DATE OF NAME CHANGE: 20150130 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Knight Therapeutics Inc CENTRAL INDEX KEY: 0001756235 ORGANIZATION NAME: STATE OF INCORPORATION: A8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41719 FILM NUMBER: 24820540 BUSINESS ADDRESS: STREET 1: 3400 BOULEVARD DE MAISONNEUVE WEST STREET 2: SUITE 1055 CITY: MONTREAL STATE: A8 ZIP: H3Z 3B8 BUSINESS PHONE: 5144844483 MAIL ADDRESS: STREET 1: 3400 BOULEVARD DE MAISONNEUVE WEST STREET 2: SUITE 1055 CITY: MONTREAL STATE: A8 ZIP: H3Z 3B8 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: 60 DEGREES PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001946563 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 452406880 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1025 CONNECTICUT AVENUE NW STREET 2: SUITE 1000 CITY: WASHINGTON STATE: DC ZIP: 20036 BUSINESS PHONE: 202-327-5422 MAIL ADDRESS: STREET 1: 1025 CONNECTICUT AVENUE NW STREET 2: SUITE 1000 CITY: WASHINGTON STATE: DC ZIP: 20036 4 1 form4.xml FORM 4 X0508 4 2023-07-28 true 0001946563 60 DEGREES PHARMACEUTICALS, INC. SXTP 0001756235 Knight Therapeutics Inc 3400 DE MAISONNEUVE W. SUITE 1055 MONTREAL A8 H3Z 3B8 QUEBEC, CANADA true Former 10% Owner 0001632373 KNIGHT THERAPEUTICS INTERNATIONAL SA DR. LUIS BONAVITA 1294, OF. 2004 MONTEVIDEO X3 11300 URUGUAY true Former 10% Owner false Common Stock, $0.0001 par value per share ("Common Shares") 2023-07-28 4 C 0 45560 4.745 A 1153897 I By Knight Therapeutics International S.A. Series A Non-Voting Convertible Preferred Stock 2023-07-28 4 C 0 2162 0 D 78803 I By Knight Therapeutics International S.A. On July 28, 2023, 60 Degrees Pharmaceuticals, Inc. (the "Issuer"), at its sole discretion, converted 2,162 shares of Series A Non-Voting Convertible Preferred Stock (the "Preferred Stock") held by Knight Therapeutics International S.A., an Uruguayan corporation ("Knight Subsidiary") into 45,560 Common Shares, at a conversion price equal to the 10 day volume weighted average price of the Common Shares immediately prior to the conversion. The Preferred Stock has a floating conversion price. Only the Issuer can cause shares of Preferred Stock to be converted into Common Shares. The conversion price of the Preferred Stock is determined in respect of the shares of Preferred Stock that are actually converted into Common Shares by the Issuer at the time of such conversion. The timing of conversion of any shares of Preferred Stock occurrence is outside of the control of the holder of the Preferred Stock. After giving effect to the transaction reported on this Form 4, Knight Subsidiary directly beneficially owns 1,153,897 Common Shares, corresponding to 9.97% ownership interest based on 11,570,578 Common Shares issued and outstanding as of April 1, 2024, and 78,803 Preferred Stock convertible only at the sole discretion of the Issuer. Knight Therapeutics Inc., a Canadian corporation ("Knight Parent" and collectively with Knight Subsidiary, the "Reporting Persons") indirectly beneficially owns 1,153,897 Common Shares, and 78,803 Preferred Stock convertible only at the sole discretion of the Issuer. None of the Reporting Persons can cause the Preferred Stock to be converted into Common Shares, and the Reporting Persons have no control over the occurrence or timing of a conversion of the Preferred Stock by the Issuer into Common Shares. The shares of Preferred Stock are not "derivative securities." The Reporting Persons do not beneficially own any of the Common Shares underlying the Preferred Stock until such time as the Issuer actually converts shares of Preferred Stock held by the Reporting Persons into Common Shares. Knight Parent is the sole owner of Knight Subsidiary and, as a result, may be deemed the beneficial owner for purposes of Securities Exchange Act of 1934 (the "Act") of any securities of the Issuer beneficially owned by Knight Subsidiary. Knight Parent disclaims beneficial ownership over all of the Common Shares beneficially owned by Knight Subsidiary, other than for the purpose of determining obligations under the Act, and the filing of this Form 4 shall not be deemed an admission that Knight Parent is the beneficial owner of such securities for any other purpose. As of March 31, 2024, the Reporting Persons are no longer beneficial owners of more than 10% of the Issuer's securities and, as such, this filing represents an exit filing for each Reporting Person. This Form 4 is being jointly filed by Knight Parent and Knight Subsidiary. Exhibit 99.1 (Joint Filer Information) incorporated herein by reference. KNIGHT THERAPEUTICS INC. By: /s/ Samira Sakhia Name: Samira Sakhia Title: President and Chief Executive Officer 2024-04-03 KNIGHT THERAPEUTICS INTERNATIONAL S.A. By: /s/ Arvind Utchanah Name: Arvind Utchanah Title: President of the Board of Directors 2024-04-03 EX-99.1 2 ef20025809_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1

Joint Filer Information
 
Name of Joint Filer:
Knight Therapeutics Inc.
   
Address of Joint Filer:
3400 de Maisonneuve W. Suite 1055, Montréal, Quebec
H3Z 3B8
   
Relationship of Joint Filer to Issuer:
Indirect Former 10% Beneficial Owner
   
Issuer Name and Ticker or Trading Symbol:
60 DEGREES PHARMACEUTICAL, INC. [SXTP]
   
Date of Event Requiring Statement:
July 28, 2023
   
Designated Filer:
Knight Therapeutics Inc.
   
Signature:
  

KNIGHT THERAPEUTICS INC.
  
   
By:
 /s/ Samira Sakhia  
Name: Samira Sakhia
  
Title: President and Chief Executive Officer
  
   
Date: April 3, 2024
  

Name of Joint Filer:
Knight Therapeutics International S.A.
   
Address of Joint Filer:
Dr. Luis Bonavita 1294, of. 2004, Montevideo, Uruguay
   
Relationship of Joint Filer to Issuer:
Direct Former 10% Beneficial Owner
   
Issuer Name and Ticker or Trading Symbol:
60 DEGREES PHARMACEUTICAL, INC. [SXTP]
   
Date of Event Requiring Statement:
July 28, 2023
   
Designated Filer:
Knight Therapeutics Inc.
   
Signature:
  

KNIGHT THERAPEUTICS INTERNATIONAL S.A.
  
   
By:
 /s/ Arvind Utchanah    
Name: Arvind Utchanah
  
Title: President of the Board of Directors
  
   
Date: April 3, 2024
  


2